SELLAS Life Sciences Group, Inc. Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation
SELLAS Life Sciences Group, Inc. (SLS) reported Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation of $573.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-13.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation · last filed 2020-03-13
- SELLAS Life Sciences Group, Inc. adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2019-06-30 was $126.00K, a 0.80% increase year-over-year.
- SELLAS Life Sciences Group, Inc. adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2019-03-31 was $185.00K, a 740.91% increase year-over-year.
- SELLAS Life Sciences Group, Inc. adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2018-12-31 was $111.00K.
- SELLAS Life Sciences Group, Inc. adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2018-09-30 was $137.00K, a 9.27% decline year-over-year.
- SELLAS Life Sciences Group, Inc. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2019 was $573.00K, a 45.06% increase from fiscal 2018.
- SELLAS Life Sciences Group, Inc. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2018 was $395.00K.
- SELLAS Life Sciences Group, Inc. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2016 was $2.26M, a 21.82% decline from fiscal 2015.
- SELLAS Life Sciences Group, Inc. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2015 was $2.90M, a 44.87% decline from fiscal 2014.
| Period end | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 3 month | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 6 month | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 9 month | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 9 month as first filed | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 12 month | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 12 month as first filed |
|---|---|---|---|---|---|---|
| 2019-12-31 | $573.00K 10-K · filed 2020-03-13 | |||||
| 2019-06-30 | $126.00K 10-Q · filed 2019-08-14 | $311.00K 10-Q · filed 2019-08-14 | $422.00K derived: sum of 3 quarters · filed 2020-03-13 | $559.00K derived: sum of 4 quarters · filed 2020-03-13 | ||
| 2019-03-31 | $185.00K 10-Q · filed 2019-05-15 | $296.00K derived: sum of 2 quarters · filed 2020-03-13 | $433.00K derived: sum of 3 quarters · filed 2020-03-13 | $558.00K derived: sum of 4 quarters · filed 2020-03-13 | ||
| 2018-12-31 | $111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $248.00K derived: sum of 2 quarters · filed 2020-03-13 | $373.00K derived: sum of 3 quarters · filed 2020-03-13 | $395.00K 10-K · filed 2020-03-13 | ||
| 2018-09-30 | $137.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $262.00K derived: sum of 2 quarters · filed 2019-08-14 | $284.00K 10-Q · filed 2018-11-14 | |||
| 2018-06-30 | $125.00K 10-Q · filed 2019-08-14 | $147.00K 10-Q · filed 2019-08-14 | ||||
| 2018-03-31 | $22.00K 10-Q · filed 2019-05-15 | |||||
| 2017-09-30 | $151.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $348.00K derived: sum of 2 quarters · filed 2017-11-09 | $576.00K 10-Q · filed 2017-11-09 | $1.01M derived: sum of 4 quarters · filed 2017-11-09 | ||
| 2017-06-30 | $197.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $425.00K 10-Q · filed 2017-08-14 | $859.00K derived: sum of 3 quarters · filed 2017-08-14 | $1.41M derived: sum of 4 quarters · filed 2017-08-14 | ||
| 2017-03-31 | $228.00K 10-Q · filed 2017-05-10 | $662.00K derived: sum of 2 quarters · filed 2017-05-10 | $1.21M derived: sum of 3 quarters · filed 2017-05-10 | $1.84M derived: sum of 4 quarters · filed 2017-05-10 | ||
| 2016-12-31 | $434.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $986.00K derived: sum of 2 quarters · filed 2017-03-15 | $1.61M derived: sum of 3 quarters · filed 2017-03-15 | $2.26M 10-K · filed 2017-03-15 | ||
| 2016-09-30 | $552.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $1.17M derived: sum of 2 quarters · filed 2016-11-09 | $1.83M 10-Q · filed 2016-11-09 | $2.60M derived: sum of 4 quarters · filed 2017-03-15 | ||
| 2016-06-30 | $622.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $1.28M 10-Q · filed 2016-08-09 | $2.05M derived: sum of 3 quarters · filed 2017-03-15 | $2.90M derived: sum of 4 quarters · filed 2017-03-15 | ||
| 2016-03-31 | $656.00K 10-Q · filed 2016-05-10 | $1.43M derived: sum of 2 quarters · filed 2017-03-15 | $2.28M derived: sum of 3 quarters · filed 2017-03-15 | |||
| 2015-12-31 | $774.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $1.62M derived: sum of 2 quarters · filed 2017-03-15 | $2.90M 10-K · filed 2017-03-15 | |||
| 2015-09-30 | $850.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $2.12M 10-Q · filed 2015-11-09 | ||||
| 2015-06-30 | $1.27M 10-Q · filed 2015-08-06 | |||||
| 2014-12-31 | $4.63M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $2.27M derived: sum of 2 quarters · filed 2017-03-15 | $3.71M derived: sum of 3 quarters · filed 2017-03-15 | $5.25M 10-K · filed 2017-03-15 | -$36.61M 10-K · filed 2015-03-05 | |
| 2014-09-30 | -$2.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-07 | -$921.00K derived: sum of 2 quarters · filed 2015-05-07 | $627.00K 10-Q · filed 2015-05-07 | $4.30M 10-Q · filed 2014-11-05 | $1.45M derived: sum of 4 quarters · filed 2016-04-15 | |
| 2014-06-30 | $1.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $2.98M 10-Q · filed 2014-08-11 | $3.80M derived: sum of 3 quarters · filed 2016-04-15 | |||
| 2014-03-31 | $1.55M 10-Q · filed 2014-05-06 | $2.37M derived: sum of 2 quarters · filed 2016-04-15 | ||||
| 2013-12-31 | $820.00K derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2016-04-15 | $1.89M 10-K/A · filed 2016-04-15 | ||||
| 2013-09-30 | $1.07M 10-Q/A · filed 2013-11-07 | |||||
| 2012-12-31 | $794.00K 8-K · filed 2015-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |